IZOTROPIC ORD SHS
IZOZF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.16M
Close$
$-0.03
135.1% downside
Current Fair Value
135.1% downsideOvervalued by 135.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $6.16 Million |
|---|---|
| Enterprise Value | $9.31 Million |
| Earnings per Share | $-0.03 |
| Beta | 2.42 |
| Outstanding Shares | 69,724,679 |
Return
| Return on Equity | 37.24% |
|---|---|
| Return on Assets | -850.73% |
| Return on Invested Capital | 24.42% |
Valuation & Multiples
| P/E Ratio | -3.39 |
|---|---|
| PEG | -13.26 |
| Price to Sales | - |
| Price to Book Ratio | -0.09 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6.24 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | -0.52 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 28, 2026
EPS Estimate
$0.01
Consensus analyst estimateRevenue Estimate
$2.03 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Izotropic Corporation
5 employees
CEO: Robert Louis Thast
Izotropic Corporation operates as a MedTech enterprise, concentrating on the commercialization of diagnostic solutions for breast cancer. Their primary focus lies in developing and offering a breast CT imaging system alongside a 3D CT br...